Norges Bank
CRNX icon

Norges Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Norges Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-149,100
Closed -$2.69M – 1981
2023
Q2 		$2.69M Hold
149,100
– – ﹤0.01% 1837
2023
Q1 		$2.39M Buy
+149,100
New +$2.76M ﹤0.01% 1902
2022
Q2 		– Sell
-25,600
Closed -$562K – 2081
2022
Q1 		$562K Sell
25,600
-21,600
-46% -$437K ﹤0.01% 2094
2021
Q4 		$1.34M Buy
47,200
+25,600
+119% +$631K ﹤0.01% 2074
2021
Q3 		$455K Sell
21,600
-51,200
-70% -$1.07M ﹤0.01% 2210
2021
Q2 		$1.37M Buy
72,800
+39,200
+117% +$689K ﹤0.01% 2065
2021
Q1 		$513K Buy
+33,600
New +$521K ﹤0.01% 2087

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank's CRNX Position: Q3 2023 in Review

Norges Bank sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 149,100 shares — an estimated $2.69M sold.

Norges Bank first reported a position in CRNX in Q1 2021 and held it in 7 quarters. The position peaked at $2.69M in Q2 2023. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

  • Norges Bank reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Norges Bank sold 149,100 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $2.69M.
  • Norges Bank first reported a position in Crinetics Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Norges Bank's Crinetics Pharmaceuticals position peaked at $2.69M in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.